Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2018
SIETES contiene 92571 citas

 
 
 1 a 20 de 356 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Puthumana J, Wallach JD, Ross JS. Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation. JAMA 2018;319:17 de julio. [Ref.ID 102793]
2. Cita con resumen
Feuerstein A. After watching Trump’s drug speech, investors poured big money into biotech funds. STAT Daily Recap 2018:4. [Ref.ID 102605]
3. Cita con resumen
Swetlitz I. Gottlieb pushes back against criticism of ‘breakthrough’ designation. STAT Daily Recap 2018:5. [Ref.ID 102595]
4. Cita con resumen
Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]
5. Cita con resumen
Alahdab F, Farah W, Almasri J, Barrionuevo P, Zaiem F, Benkhadra R, Asi N, Alsawas M, Pang Y, Ahmed AT, Rajjo T, Kanwar A, Benkhadra K, Razouki Z, Murad MH Wang Z. Treatment effect in earlier trials of patients with chronic medical conditions: a meta-epidemiologic study. Mayo Clin Proc 2018;93:marzo. [Ref.ID 102499]
6.Tiene citas relacionadas Cita con resumen
Jonker CJ, van den Berg HM, Kwa MSG, Hoes AW, Mol PGM. Registries supporting new drug applications. Pharmacoepidemiol Drug Saf 2017;27:1451-7. [Ref.ID 102187]
7. Cita con resumen
Anónimo. Dutch health minister considers compulsory license over drug prices. DIA Daily 2017:1. [Ref.ID 102148]
8. Cita con resumen
9. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
12.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
13. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
14.Tiene citas relacionadas Cita con resumen
Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017;26:26 de marzo. [Ref.ID 101903]
17. Cita con resumen
Huang Z, Ma J. Chronic purulent nasal discharge. BMJ 2017;357:j2061. [Ref.ID 101636]
18. Cita con resumen
Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:26 de mayo. [Ref.ID 101602]
19. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
20. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
Seleccionar todas
 
 1 a 20 de 356 siguiente >>